Agios Pharmaceuticals, Inc. - AGIO STOCK NEWS

On April 12, 2023, Totus Medicines announced the appointment of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero to its Scientific Advisory Board (SAB). The company, known for its innovative drug discovery platform, aims to revolutionize oncology treatment using its Totus Accel^™ technology, which significantly speeds up drug discovery processes. Dr. Cantley is renowned for discovering the PI3K pathway, while Dr. Rugo has established critical clinical strategies for rapid drug approvals. Dr. Tabernero leads several oncology initiatives at Vall d'Hebron Institute. This diverse SAB aims to guide Totus as it progresses into clinical trials, enhancing its capabilities in addressing complex oncology challenges, especially targeting the mutated oncogene PI3Kα.

Agios Pharmaceuticals (NASDAQ: AGIO) announced its participation in two investor conferences scheduled for March 2023. The Cowen 43rd Annual Health Care Conference is set for March 6 at 1:30 p.m. ET, followed by the Oppenheimer 33rd Annual Healthcare Conference on March 13 at 12:00 p.m. ET. Live webcasts of these presentations will be available on Agios’s website under the 'Events & Presentations' section, with replays archived for two weeks post-event. Agios is recognized for its innovative therapies aimed at rare diseases and is advancing a strong clinical pipeline.

Agios Pharmaceuticals has launched the Red Blood Cell Advisory Council to unite patients, caregivers, and physicians focused on hemolytic anemias such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. This multi-stakeholder initiative aims to drive awareness and generate solutions relevant to these diseases. As stated by the Chief Medical Officer, the goal is to create a platform to amplify the voices of affected communities. Through this council, Agios seeks to foster collaboration across disease areas and improve quality of life for patients. Additionally, the company is supporting related initiatives during February, including Rare Disease Day.

Agios Pharmaceuticals (AGIO) announced significant progress in its developments during the fourth quarter of 2022, particularly with the U.S. launch of PYRUKYND®, generating $4.3 million in net revenue. The company completed enrollment in the Phase 2 RISE UP study for sickle cell disease and is on track for Phase 3 studies in thalassemia. Agios reported a net income of $36.5 million for Q4 2022, contrasting with a net loss of $98.6 million in Q4 2021, while total revenue for the year was $11.7 million. The company holds $1.1 billion in cash, expected to support ongoing operations and development without additional equity rises.

Agios Pharmaceuticals (Nasdaq: AGIO) will host a conference call and live webcast on February 23, 2023, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2022 financial results. The event will be accessible via the Investors section on Agios’s official website. The company is known for its role in cellular metabolism and its marketing of a first-in-class pyruvate kinase activator for adults with PK deficiency, a rare hemolytic anemia. Agios is also advancing a clinical pipeline targeting various blood disorders, including sickle cell disease and thalassemia.

Agios Pharmaceuticals (Nasdaq: AGIO) announced its strategic vision for 2023 and beyond, focusing on pivotal trials in rare hematological diseases. They are on track for potential FDA approvals for PYRUKYND in thalassemia in 2025 and sickle cell disease in 2026. With a strong cash position, Agios aims to complete its ongoing programs and expand its pipeline towards cash-flow positivity. Key milestones include enrolling half of patients in ongoing studies and presenting data at the J.P. Morgan Healthcare Conference on January 11, 2023.

Agios Pharmaceuticals (Nasdaq: AGIO) announced the grant of inducement equity awards to newly appointed Chief Commercial Officer, Tsveta Milanova, effective January 3, 2023. The awards include a nonstatutory stock option for 135,682 shares at an exercise price of $27.53, restricted stock units for 25,426 shares, and performance stock units for 10,897 shares. The option vests over four years, while restricted stock units vest annually for three years. These grants comply with Nasdaq Listing Rule 5635(c)(4), indicating their significance in Milanova's employment.

Agios Pharmaceuticals, a leader in rare disease therapies, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT. The presentation will be accessible via a live webcast on the company’s website, with a replay available for at least two weeks afterward. Agios markets a first-in-class pyruvate kinase activator and is advancing a clinical pipeline focused on diseases like sickle cell disease and thalassemia. For more information, visit www.agios.com.